Chi-GVM Regimen for the Treatment of R/R PTCL

Inclusion Criteria:

• 1. R/R PTCL confirmed by pathological tissue [including peripheral T-cell lymphoma-nototherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and ALK+anaplastic large cell lymphoma (ALCL) , ALK-ALCL, monotypic epithelial intestinalT-cell lymphoma (MEITL), etc.], the diagnostic criteria refer to the 2022 WHOdiagnostic criteria; 2. Have had at least one previous systemic treatment [includingchemotherapy, autologous hematopoietic stem cell transplantation (ASCT) ), etc.]Patients who have no remission or relapse after remission; 3. Sign written informedconsent and be able to comply with the visits and related procedures specified in theprotocol; 4. Whole-body PET/CT performed 28 days before study enrollment must be Atleast 1 evaluable or measurable lesion that meets the Lugano2014 criteria: lymph nodelesions, measurable lymph nodes must have a long diameter >1.5 cm; non-lymph nodelesions, measurable extranodal lesions must have a long diameter >1.0 cm; 5. ECOG PSscore: 02; 6. Have adequate organ and bone marrow function, defined as follows:neutrophil count ≥1.5×109/L, platelet count ≥75×109/L, hemoglobin ≥80 g/L (neutrophilcount in patients with bone marrow involvement) The granulocyte count can be relaxedto ≥1.0×109/L, the platelet count can be relaxed to ≥50×109/L, and the hemoglobin canbe relaxed to ≥75 g/L); 7. Liver and renal function: Serum creatinine (Cr) ≤1.5 timesthe upper limit of normal values; aspartate aminotransferase (AST) and alanineaminotransferase (ALT) ≤2.5 times the upper limit of normal values (≤5 times the upperlimit of normal values for patients with liver invasion); total bilirubin (TBIL) ) ≤ 1.5 times the upper limit of normal value (for patients with liver invasion ≤ 3 timesthe upper limit of normal value); 8. Expected survival time more than 3 months; 9. Age 1875 years old.

Exclusion Criteria:

• 1. The subject's previous anti-tumor treatment history meets one of the followingconditions:

1. Those who have received mitoxantrone or Mitoxantrone Hydrochloride Liposome inthe past;
2. Previously received treatment with doxorubicin or other anthracyclines, with atotal cumulative dose of doxorubicin >360 mg/m2 (converted from otheranthracyclines, 1 mg of doxorubicin is equivalent to 2 mg of epirubicin );
3. Patients who have received ASCT within 100 days of first medication, or havereceived allogeneic hematopoietic stem cell transplantation (Allo-SCT);
4. Within 4 weeks before using this study drug for the first time, you have receivedanti-tumor treatment (including chemotherapy, targeted therapy, hormone therapy,taking traditional Chinese medicine with anti-tumor activity, etc.) orparticipated in other clinical trials and received clinical trial drugs.
5. Have a hypersensitivity reaction to any study drug or its ingredients; 3.Uncontrollable systemic diseases (such as advanced infection, uncontrollablehypertension, diabetes, etc.); 4. Heart function and disease meet one of the followingconditions:
6. Long QTc syndrome or QTc interval >480 ms;
7. Complete left bundle branch block, II or III degree atrioventricular block;
8. Severe, uncontrolled arrhythmia requiring drug treatment;
9. New York Heart Association classification ≥ III;
10. The cardiac left ventricular ejection fraction (LVEF) is less than 50%;
11. Have a history of myocardial infarction, unstable angina, severe unstableventricular arrhythmia or any other arrhythmia requiring treatment, clinicallysevere pericardial disease, or acute ischemic or active disease within 6 monthsbefore recruitment Electrocardiographic evidence of sexual conduction systemabnormalities.
12. Active infection of hepatitis B and hepatitis C (hepatitis B virus surface antigenis positive and hepatitis B virus DNA exceeds 1×103 copies/mL; hepatitis C virus RNAexceeds 1×103 copies/mL); 6. Human immunodeficiency virus (HIV) infection (HIVantibody positive); 7. Have suffered from other malignant tumors in the past or at thesame time (except for non-melanoma basal cell carcinoma of the skin, breast/cervicalcarcinoma in situ and other malignant tumors that have been effectively controlledwithout treatment in the past 5 years); 8. Suffer from primary or secondary centralnervous system (CNS) lymphoma or have a history of CNS lymphoma at the time ofrecruitment; 9. Pregnant, lactating women and patients of childbearing age who areunwilling to take contraceptive measures; 10. People with mental disorders/peopleunable to obtain informed consent; 11.Those who are judged by the researcher to beunsuitable to participate in this trial